No insider purchase over the last 90 days. The latest was filed 13 May 2025.
This page follows insider dealings at Equasens as filed with AMF, a company from the Healthcare & Pharma sector. Equasens has had no insider filing for more than a year; the last one goes back to 13 May 2025.
The full history, which starts in 2021, counts 6 purchases against 1 sale.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. This summary is built from AMF disclosures alone and does not predict where the share price will go.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Equasens Strong Buy (bullish), based on 4 analysts. Average price target: €52.30.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
7 of 7 declarations
Equasens is a leading European provider of digital solutions for healthcare professionals. Listed on Euronext Paris under the ticker EQS and ISIN FR0012882389, the group has been built over more than 35 years around a highly specialized positioning in software, services and connected equipment for the healthcare ecosystem. Headquartered historically in Villers-lès-Nancy, it has become one of the best-known French healthcare software publishers, with deep expertise in digitizing pharmacies, healthcare institutions and independent practitioners. The group now employs more than 1,500 people across Europe and is included in the Euronext Tech Leaders segment, reinforcing its profile as a technology company with a significant recurring-revenue base.
Equasens’ core business is the design, publishing and integration of business software, cloud services, interoperability solutions and related hardware for healthcare players. Its offering spans retail pharmacies, medical practices, care facilities, health networks and, more broadly, public and private healthcare organizations. In recent years, the group has advanced a platform strategy that goes beyond its historical software base to include higher-value services such as digital training, telehealth, SaaS solutions and sovereign healthcare data infrastructure. Recent acquisitions including Erevo, Calimed, Digipharmacie, as well as businesses related to DIS and Résurgences, illustrate a development strategy that combines organic growth with targeted bolt-on acquisitions.
Geographically, Equasens has a strong footprint in France and an expanding European presence, with operations reported in Germany, Great Britain, Belgium, Ireland, Italy and Luxembourg. This multi-country setup enables the company to serve a diverse customer base while adapting to local healthcare workflows and regulations. In 2025, the group reported revenue of €236.5 million, up 9.1%, EBITDA of €66.7 million and net profit of €41.1 million, confirming a profitable model supported by growing recurring revenues. Its strategy is centered on innovation, the strengthening of its healthcare ecosystem and the upgrade of its service offering, making Equasens a structural player in the digital transformation of healthcare in Europe.
Purchases our model currently ranks for the recommendations list.
All recommendations